HLA Typing Companies

The global HLA typing market is expected to reach USD 1.7 billion in 2025 and account for USD 2.3 billion by 2030, with a CAGR of 6.0% from 2025 to 2030.

The growth of the HLA typing market is driven by the increasing testing capacity of environmental laboratories, regulatory changes, and the expanding range of applications. The global development of the pharmaceutical and biotechnology industries, along with significant R&D investments from biopharma companies, rising funding for life sciences research, and a heightened demand for high-throughput screening, are also driving the market. Moreover, the shift toward precision and accuracy in information, along with increasing productivity costs, is expediting the integration of automation technologies.

To know about the assumptions considered for the study download the pdf brochure

As of 2024, the key players operating in the global HLA typing market are Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F- Hoffman-La Roche Ltd (Switzerland), Accelerate Diagnostics, Inc. (US), and others. Companies are focusing on strategies such as product launches and acquisitions to stay competitive. For instance, in November 2023, Roche launched the next-generation qPCR system to advance clinical needs in molecular diagnostics. In October 2023, Eurobio Scientific (US) acquired Genome Diagnostics BV (GenDx) (Netherlands), a company specializing in molecular diagnostics for transplantation.

F. HOFFMANN-LA ROCHE LTD (ROCHE) (SWITZERLAND)

F. Hoffmann-La Roche Ltd (Roche) is a diversified global healthcare leader with major pharmaceutical and diagnostics presence, selling its HLA (human leukocyte antigen) products through the Molecular Diagnostics segment. The company offers a digital PCR system, which has strengthened its diagnostic capability along with sales channels. It has a strong global supply chain and strong R&D. Its main leadership approaches in the HLA typing market involve incorporating leading-edge automation technologies, growth in emerging regions, research collaborations, and strategic investment in next-generation sequencing technologies to enhance the speed and accuracy of diagnostic solutions.

BECTON, DICKINSON AND COMPANY (US)

Becton, Dickinson and Company (BD) is a major worldwide medical technology corporation specializing in medical device research and development, manufacturing, and distribution, as well as diagnostic systems and reagents. The company provides HLA typing and transplant diagnostics under the BD Life Sciences segment. To maintain growth in these competitive HLA typing markets, the company is focused on expanding in emerging markets, namely the Asia Pacific region, and managing challenges such as pricing pressures and possible economic shocks that may impact revenue. Its areas of core competencies are vast international reach, comprehensive diagnostics capabilities, robust R&D capabilities, and good regulatory compliance. Its strategic direction areas include leadership in innovation in transplant diagnostics, exploitation of automation technologies, and strategic partnerships to increase its market space.

Market Ranking

The top five market players held roughly 60 to 65% market share globally in 2024. BD has the largest portfolio within the life sciences product space, emphasizes product innovation and product quality through R&D investments for the lowest cost, quality, and value, and has customers in over 190 countries. Thermo Fisher Scientific Inc. operates in four segments and utilizes its Life Sciences Solutions segment to promote PCR- and NGS-based reagents, instruments, and software for HLA typing as ONE LAMBDA. Roche has a strong brand for product quality, which it consistently produces to maintain its broad customer base and supports expansion into high-growth regions, such as Asia Pacific, to diversify its revenue stream globally. The remainder of the market (approximately 35 to 40%) includes regional and niche competitors that promote innovation while leveraging opportunities for startups. Competitive dynamics in the market are driven by more demand for higher throughput, more precise data, and integrated HLA typing products and services.

Related Reports:

HLA Typing Market by Technology (PCR (SSO, SSP, Real-time), Sequencing (NGS, Sanger's)), Product (Instruments, Reagents, Software), Application (Donor-recipient Cross-matching, Transfusion, Cancer), End User (Hospitals, Reference Labs) Global Forecasts to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com